Editorial Commentary
Do we have a “game changer” in treating patients with brain metastasis from renal cell carcinoma?
Abstract
Renal cell carcinoma (RCC) is the most common type of kidney cancer. About 25% of patients are diagnosed with metastatic disease at presentation and another 25–30% diagnosed with localized disease will develop metastasis over time (1). The incidence of brain metastasis (BM) ranged from 3–17% in various studies.